Yiyeon Pharmaceutical pursues asset securitization of Chungju plant... "Secure ₩100B, will create business synergy"
Predicted impact: Medium
Plant securitization targeting ₩100B, about 54% of market value, though it is financing, not equity.
Reyon Pharmaceutical이연제약
102460 · KOSPI · ₩102460 · 이연제약
₩9,720▼ ₩10 (0.10%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −11.96%
- Market cap
- ₩181B
- Enterprise value
- ₩263B
- P/E
- —
- P/B
- 0.9×
- Dividend yield
- 0.0%
- ROE
- −17.6%
- Net margin
- −23.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−26.4% from the high
₩9,100Today: ₩9,310 – ₩9,730₩13,200
Returns
- 1W−2.2%
- 1M−3.6%
- 3M−1.4%
- 6M−13.1%
- YTD−9.8%
- 1Y−12.0%
- Volume today
- 47,093
- 1.6× the 20-day average
- Traded today
- ₩447M
- Listed shares
- 18,586,811
- EPS (12 months)
- −₩1,842
- Earnings yield −19.0%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 52 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: The filings are routine corporate notices about bond buybacks and price adjustments, with no clear positive or negative signal. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat-2.9% over the last month; the price is below its 20-day average.
- News impactSome8 news items and filings in two weeks; 0 rated high impact, 3 medium.
Signals describe activity, not recommendations. Not financial advice.
Reyon Pharmaceutical stock overview
Reyon Pharmaceutical (이연제약, KRX: 102460) is listed on KOSPI, in the Biotech & Pharma sector. The company, founded in 1964, develops, manufactures and sells prescription pharmaceuticals in South Korea. Its shares closed at ₩9,720 on Oct 27, 2026, down 0.10% on the day, giving it a market value of ₩181B.
Key facts
- Market cap
- ₩181B
- Sector
- Biotech & Pharma
- Latest price change
- −0.10%
- As of
- Oct 27, 2026
- Main business
- The company, founded in 1964, develops, manufactures and sells prescription pharmaceuticals in South Korea.
Quick answers about Reyon Pharmaceutical
- What does Reyon Pharmaceutical do?
- The company, founded in 1964, develops, manufactures and sells prescription pharmaceuticals in South Korea. Its revenue comes from prescription drugs across areas such as antibiotics, cardiovascular, digestive and respiratory care, from original products including the CT contrast agent Optiray, which it distributes under an exclusive domestic supply agreement, and from active pharmaceutical ingredients such as tacrolimus and teicoplanin. It is building biologics and chemical drug pipelines and a production platform, anchored by its Chungju plant, which has GMP certifications and aims to offer contract manufacturing.
- What is the market cap of Reyon Pharmaceutical?
- The market capitalisation of Reyon Pharmaceutical was ₩181B at the close on Oct 27, 2026.
- Who are the largest shareholders of Reyon Pharmaceutical?
- According to the latest official filings, the largest reported holders are Jung Soon-ok (53.84%, as of Oct 8, 2026); Premier Growth Strategy M&A No. 3 Private Equity Fund (11.89%, as of Oct 29, 2024); Quad Asset Management (10.77%, as of Jul 9, 2025).
- When is the next earnings report from Reyon Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Reyon Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Reyon Pharmaceutical?
- Yes. The National Pension Service held 0.61% of Reyon Pharmaceutical shares as of Dec 31, 2025.
Company profile
The company, founded in 1964, develops, manufactures and sells prescription pharmaceuticals in South Korea. Its revenue comes from prescription drugs across areas such as antibiotics, cardiovascular, digestive and respiratory care, from original products including the CT contrast agent Optiray, which it distributes under an exclusive domestic supply agreement, and from active pharmaceutical ingredients such as tacrolimus and teicoplanin. It is building biologics and chemical drug pipelines and a production platform, anchored by its Chungju plant, which has GMP certifications and aims to offer contract manufacturing.
Written by AI from the company's latest annual report.
- Korean name
- 이연제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 정순옥, 유용환 (각자 대표이사)
- Founded
- Nov 1964
- Listed
- Jun 2010
- Listed shares
- 18,586,811
- Fiscal year ends
- Month 12
- Website
- reyonpharm.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Eyes Pharma Partner Elixirgen Wins 'Bayer Corlab Connect Seoul'
Predicted impact: Medium· Actual: −9.3% vs sector, volume 1.3× normal (5 trading days)
Amended convertible bond issue decision; dilution size not stated in data.
Recent filings
See all- Amended: Convertible bond issue decisionOct 27, 2026
- Adjustment of Conversion Price, Warrant Exercise Price and Exchange Price (Informational Disclosure)Oct 26, 2026
- Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)Oct 26, 2026
- 5%+ holding reportOct 20, 2026
- Adjustment of Conversion Price, Warrant Exercise Price and Exchange Price (Informational Disclosure)Oct 16, 2026
Titles in Korean until English translations are added.
Also known as: Reyon Pharmaceutical / 이연제약 / 102460 / KRX:102460
Source: KRX statistical information